<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01421186</url>
  </required_header>
  <id_info>
    <org_study_id>MOR202C101</org_study_id>
    <secondary_id>DRKS00003145</secondary_id>
    <nct_id>NCT01421186</nct_id>
  </id_info>
  <brief_title>A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase I/IIa, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of the Human Anti-CD38 Antibody MOR03087 as Monotherapy and in Combination With Standard Therapy in Subjects With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MorphoSys AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MorphoSys AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicentre, dose escalation study to characterize the safety and
      preliminary efficacy of the human anti-CD38 antibody MOR03087 (MOR202), in adult subjects
      with relapsed/refractory multiple myeloma, as monotherapy and in adult subjects with
      relapsed/refractory multiple myeloma in combination with standard therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of maximum tolerated dose and / or recommended dose and dosing regimen of MOR03087</measure>
    <time_frame>First cycle of treatment</time_frame>
    <description>As monotherapy
In combination with dexamethasone
In combination with pomalidomide + dexamethasone
In combination with lenalidomide + dexamethasone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety will be evaluated by assessing adverse events, clinical laboratory data and vital signs</measure>
    <time_frame>until PD, maximum 2 years after 1st dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who develop anti-MOR03087 antibodies as a measure of immunogenicity</measure>
    <time_frame>until PD, maximum 2 years after 1st dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MOR03087 +/- lenalidomide or pomalidomide (pharmacokinetic assessment comprises: C max, t max, t 1/2, CL, AUC)</measure>
    <time_frame>until PD, maximum 2 years after 1st dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate, duration of response, time to progression (TTP) and progression-free survival (PFS)</measure>
    <time_frame>maximum 2 years after 1st dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Phase 1 dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: MOR03087 dose escalation; biweekly treatment
Part B: MOR03087 dose escalation; weekly treatment
Part C: MOR03087 dose escalation (weekly treatment) + dexamethasone
Part D: MOR03087 weekly treatment in combination with pomalidomide + dexamethasone
Part E: MOR03087 weekly treatment in combination with lenalidomide + dexamethasone
For all parts, patients will be treated until disease progression or until a maximum of 2 years after first treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a confirmatory cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Confirmatory cohorts of MOR03087 monotherapy (plus or minus dexamethasone), in combination with pomalidomide plus dexamethasone, and in combination with lenalidomide plus dexamethasone.
Following completion of Parts A, B, and C (dose escalation of MOR03087 biweekly and weekly schedules), the MTD or recommended dose and dosing regimen will be confirmed in a minimum of 6 subjects.
Following completion of Parts D (dose escalation of MOR03087 in combination with pomalidomide + dexamethasone) and E (dose escalation of MOR03087 in combination with lenalidomide + dexamethasone), the MTD and/or recommended dose in each part will be confirmed in a minimum of 6 subjects.
For all parts, patients will be treated until disease progression or until a maximum of 2 years after first treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOR03087 phase 1 dose escalation</intervention_name>
    <description>Treatment cycles will be 28 days. Initial MOR03087 doses will be 0.01 mg/kg in part A, 4 mg/kg in parts B and C and 8 mg/kg in parts D and E; in all parts MOR03087 doses will be escalated to a maximum of 16 mg/kg. In part A, patients will receive a biweekly intravenous infusion of MOR03087 which will be administered on days 1 and 15 of the cycle. In parts B to E patients will receive a weekly intravenous infusion of MOR03087 which will be administered on days 1, 8, 15, and 22 of the cycle.
In all parts a loading dose of MOR03087 will be additionally administered on day 4 of cycle 1.</description>
    <arm_group_label>Phase 1 dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOR03087</intervention_name>
    <description>MOR03087 will be administered according to the MTD or recommended dose and dosing regimen for MOR03087 from parts A-E of the phase I dose escalation. The biweekly MOR03087 regimen as described in part A; the weekly regimen as described for parts B-E.</description>
    <arm_group_label>Phase 2a confirmatory cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone will be administered to patients orally; 40 mg (≤ 75 years old) or 20 mg (&gt; 75 years old) on days 1, 8, 15, and 22 of the 28-day cycle. An additional dose will be administered in cycle 1 on day 4.</description>
    <arm_group_label>Phase 1 dose escalation</arm_group_label>
    <arm_group_label>Phase 2a confirmatory cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Pomalidomide will be administered to patients orally 4 mg on days 1-21 of the 28-day cycle.</description>
    <arm_group_label>Phase 1 dose escalation</arm_group_label>
    <arm_group_label>Phase 2a confirmatory cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide will be administered to patients orally 25 mg on days 1-21 of the 28-day cycle.</description>
    <arm_group_label>Phase 1 dose escalation</arm_group_label>
    <arm_group_label>Phase 2a confirmatory cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects 18 years and older

          2. Relapsed or refractory multiple myeloma defined as:

             Parts A, B and C:

             (i) Failure of at least 2 previous therapies which must have included an
             immunomodulatory agent and a proteasome inhibitor (either together or part of
             different therapies) (ii) All subjects must have documented progression during or
             after their last prior therapy for multiple myeloma

             Part D:

             (i) At least 2 previous therapies including lenalidomide and a proteasome inhibitor
             (ii) All subjects must have documented progression during or within 60 days after
             their last prior therapy for multiple myeloma

             Part E:

             (i) Received at least one previous therapy (ii) All subjects must have documented
             progression during or after their last prior therapy for multiple myeloma

          3. Presence of serum M-protein ≥ 0.5 g per 100 mL (≥ 5 g/L) and / or urine M-protein ≥
             200 mg per 24-hour period

          4. Absolute neutrophil count (ANC) ≥ 1,000 / mm3

          5. Haemoglobin ≥ 8 g/dL

          6. Ability to comply with all study related procedures, medication use and evaluations

        Exclusion Criteria:

          1. Primary refractory multiple myeloma

          2. History of significant cerebrovascular disease or sensory or motor neuropathy of
             toxicity grade 3 or higher

          3. Treatment with systemic investigational agent within 28 days prior to first study
             treatment

          4. Solitary plasmacytoma or plasma cell leukaemia

          5. Previous allogenic SCT

          6. Prior therapy with other monoclonal antibodies targeting the CD38 antigen or prior
             therapy with other IgG monoclonal antibodies within 3 months prior to first study
             treatment, or IgM monoclonal antibodies within 1 month prior to first study treatment

          7. Active systemic infection

          8. Systemic disease preventing study treatment

          9. Multiple myeloma with CNS involvement

         10. Previous treatment with cytotoxic chemotherapy or large field radiotherapy or other
             myeloma specific therapy within 28 days prior to first study treatment (radiation to a
             single site as concurrent therapy is allowed)

         11. Significant uncontrolled cardiovascular disease or cardiac insufficiency (New York
             Heart Association [NYHA] classes III, IV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AKH (Allgemeines Krankenhaus der Stadt Wien), Abteilung für Klinische Onkologie, Universitätsklinik für Innere Medizin I</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, CBF: Campus Benjamin Franklin, CC 14: Tumormedizin, Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik 5 - Hämatologie und Internist. Onkologie, Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik, Abt. Innere Medizin I</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäsklinikum Heidelberg, Klin.-Pharmakologisches Studienzentrum</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sektion für Stammzell- und Immuntherapie, II. Medizinischen Klinik,</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar/ Studien / III. Med. Klinik</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik II, Abt. Hämatologie, Onkologie,</name>
      <address>
        <city>Tübingen</city>
        <zip>7206</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Studienambulanz für Hämatologie/Onkologie und Infektiologie</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2011</study_first_submitted>
  <study_first_submitted_qc>August 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2011</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>MOR03087 (MOR202)</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Pomalidomide</keyword>
  <keyword>CD38</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

